BRSY.F Stock Overview
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BrainsWay Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪2.47 |
| 52 Week High | ₪2.97 |
| 52 Week Low | ₪0.90 |
| Beta | 0.34 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -40.48% |
| 5 Year Change | -55.09% |
| Change since IPO | 105.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRSY.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 33.5% | -4.1% | -3.7% |
| 1Y | n/a | -2.2% | 20.5% |
Return vs Industry: Insufficient data to determine how BRSY.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how BRSY.F performed against the US Market.
Price Volatility
| BRSY.F volatility | |
|---|---|
| BRSY.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BRSY.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BRSY.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 134 | Hadar Levy | www.brainsway.com |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.
BrainsWay Ltd. Fundamentals Summary
| BRSY.F fundamental statistics | |
|---|---|
| Market cap | US$84.53m |
| Earnings (TTM) | -US$4.20m |
| Revenue (TTM) | US$31.79m |
2.7x
P/S Ratio-20.5x
P/E RatioIs BRSY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRSY.F income statement (TTM) | |
|---|---|
| Revenue | US$31.79m |
| Cost of Revenue | US$8.31m |
| Gross Profit | US$23.48m |
| Other Expenses | US$27.67m |
| Earnings | -US$4.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 73.86% |
| Net Profit Margin | -13.20% |
| Debt/Equity Ratio | 0% |
How did BRSY.F perform over the long term?
See historical performance and comparison